Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-26. (Canceled)

27. (Previously Presented) A method for activating T cells in a subject, the method comprising administering to the subject an amount of a cytochrome P450 CYP1B1 sequence effective to activate T cells that recognize a CYP1B1 epitope.

28. (Previously Presented) The method of claim 27, wherein activation of T cells is achieved by immunizing a human with a CYP1B1 amino acid sequence.

29. (Previously Presented) The method of claim 28, wherein the immunizing the human with the CYP1B1 amino acid sequence activates cytotoxic T cells.

30. (Previously Presented) The method of claim 28, wherein the immunizing the human with the CYP1B1 amino acid sequence activates helper T cells.

31. (Previously Presented) The method of claim 28, wherein the human has a cancer.

32. (Previously Presented) The method of claim 31, wherein the cancer is in the bladder, brain, breast, colon, connective tissue, kidney, lung, lymph node, esophagus, ovary, skin, stomach, testis, or uterus.

33. (Previously Presented) The method of claim 31, wherein the immunization results in a cell-mediated or humoral immune response against the cancer.

34. (Previously Presented) The method of claim 28, wherein the CYP1B1 amino acid sequence comprises ESLRPGAAPRDMMD (SEQ ID NO:1).

35. (Previously Presented) The method of claim 28, wherein the CYP1B1 amino acid sequence comprises EKKAAGDSHGGGAR (SEQ ID NO:2).

36-40. (Canceled)

41. (New) The method of claim 27, wherein subject is a human.

42. (New) The method of claim 41, wherein the human has a cancer.

43. (New) The method of claim 42, wherein the cancer is in the bladder, brain, breast, colon, connective tissue, kidney, lung, lymph node, esophagus, ovary, skin, stomach, testis, or uterus.

44. (New) The method of claim 42, wherein the administration results in a cell-mediated or humoral immune response against the cancer.